5 December 2019 - - UK-based human antibodies specialist Iontas Ltd. has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells, the company said.

The agreement is to generate and optimise antibodies for novel immuno-oncology targets, including access to Iontas' proprietary Mammalian Display technology to select antibodies with optimal biophysical properties.

Iontas' proprietary technology enables the construction of large libraries of stable cell lines displaying human antibodies on their surface.

As well as generating an abundance of therapeutic antibody leads, the technology also addresses "developability" issues early in discovery; increasing the likelihood of successful progress through the development process.

Under the terms of the collaboration, the project provides Adaptate Biotherapeutics with access to Iontas' proprietary Mammalian Display technology, allowing the selection of high affinity antibodies based on their function, stability, expression and developability thereby facilitating a speedy transition through Chemistry, Manufacturing and Controls and eventual manufacturing.